Maze Therapeutics (NASDAQ:MAZE) Given “Buy” Rating at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $110.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 291.60% from the stock’s current price.

MAZE has been the subject of several other reports. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday. Citigroup initiated coverage on Maze Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $63.40.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $28.09 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65. The firm has a market capitalization of $1.56 billion, a P/E ratio of -11.15 and a beta of 2.17. The business’s 50-day simple moving average is $27.18 and its 200-day simple moving average is $29.17.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Equities analysts predict that Maze Therapeutics will post -2.72 EPS for the current year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 9,705 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 3,243 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $84,350.43. Following the completion of the sale, the insider owned 32,316 shares in the company, valued at approximately $840,539.16. This trade represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 191,459 shares of company stock worth $5,263,539. 5.30% of the stock is owned by company insiders.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the second quarter valued at $122,983,582. Alphabet Inc. purchased a new position in Maze Therapeutics during the 2nd quarter valued at about $41,435,000. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $133,502,907. Frazier Life Sciences Management L.P. boosted its holdings in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares during the period. Finally, Hhlr Advisors LTD. purchased a new position in Maze Therapeutics in the second quarter valued at about $10,922,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.